Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Liminal BioSciences Inc. (LMNL : NSDQ)
 
 • Company Description   
Liminal BioSciences Inc. is a biotechnology company. It engages in discovering, developing and commercializing novel small molecule compounds for respiratory, liver and renal diseases. The company's product pipeline consists of PBI-4050, which are in clinical stage. Liminal BioSciences Inc., formerly known as Prometic Life Sciences Inc., is based in Laval, Canada.

Number of Employees: 48

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.58 Daily Weekly Monthly
20 Day Moving Average: 47,018 shares
Shares Outstanding: 31.04 (millions)
Market Capitalization: $18.00 (millions)
Beta: 1.57
52 Week High: $6.30
52 Week Low: $0.37
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.47% -20.55%
12 Week -31.76% -24.97%
Year To Date -46.79% -34.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
440 Armand-Frappier Boulevard Suite 300
-
Laval,A8 H7V 4B4
CAN
ph: 1-450-781-0115
fax: 1-450-781-4477
investor@liminalbiosciences.com http://www.liminalbiosciences.com
 
 • General Corporate Information   
Officers
Bruce Pritchard - Chief Executive Officer
Alek Krstajic - Chairman
Patrick Sartore - President
Nicole Rusaw - Chief Financial Officer
Simon Best - Director

Peer Information
Liminal BioSciences Inc. (CORR.)
Liminal BioSciences Inc. (RSPI)
Liminal BioSciences Inc. (CGXP)
Liminal BioSciences Inc. (BGEN)
Liminal BioSciences Inc. (GTBP)
Liminal BioSciences Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 53272L103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 31.04
Most Recent Split Date: 7.00 (0.00:1)
Beta: 1.57
Market Capitalization: $18.00 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.24 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.98
Price/Cash Flow: -
Price / Sales: 35.30
EPS Growth
vs. Year Ago Period: 46.15%
vs. Previous Quarter: -21.74%
Sales Growth
vs. Year Ago Period: -76.20%
vs. Previous Quarter: 40.00%
ROE
03/31/22 - -246.63
12/31/21 - -514.74
09/30/21 - -1,294.21
ROA
03/31/22 - -38.71
12/31/21 - -45.40
09/30/21 - -58.90
Current Ratio
03/31/22 - 2.77
12/31/21 - 6.20
09/30/21 - 6.21
Quick Ratio
03/31/22 - 2.77
12/31/21 - 6.20
09/30/21 - 6.21
Operating Margin
03/31/22 - -
12/31/21 - -7,950.20
09/30/21 - -4,550.04
Net Margin
03/31/22 - -
12/31/21 - 3,107.45
09/30/21 - -654.71
Pre-Tax Margin
03/31/22 - -8,338.08
12/31/21 - -6,990.64
09/30/21 - -6,025.47
Book Value
03/31/22 - 0.59
12/31/21 - 0.87
09/30/21 - 1.27
Inventory Turnover
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.13
Debt-to-Equity
03/31/22 - 0.62
12/31/21 - 1.58
09/30/21 - 1.14
Debt-to-Capital
03/31/22 - 38.12
12/31/21 - 61.26
09/30/21 - 53.28
 

Powered by Zacks Investment Research ©